Industry: Life Sciences Region: Sweden Transaction Price: US $1million Transaction Method: Equity investment
Project Introduction:
It's a biotech company focused on treating rare tumors.
The company develops and commercializes novel medicines for met or unmet medical needs with a clear path to development and market.
The company has two drug candidates in clinical development: Mangoral and Oncoral.
About Mangoral
Mangoral (Manganese Chloride Tetrahydrate) is a new oral contrast agent for MR imaging designed to improve the detection and visualization of focal liver lesions, including liver metastases and primary tumors, in patients with renal insufficiency. These patients may suffer severe side effects from the contrast-type contrast agents commonly used today. Mangoral, which has been granted orphan drug status by the US Food and Drug Administration, is currently in phase 3 development.
About Oncoral Oncoral
This is a new oral irinotecan tablet that is being developed. Irinotecan is a chemotherapy that is known to have effective anti-tumor effects, even in hard-to-treat cancers. Oncoral is a daily tablet that has the potential to provide better patient outcomes and improved safety after daily tablet treatment compared to high-dose intravenous infusion in hospitals. Oncoral was originally developed to treat stomach cancer. Following successful phase 1 results, preparations are underway for phase 2 clinical development of OnCoral.
Cooperation Intention:
The company hopes to seek strategic partners in the Chinese market to jointly develop the Chinese market.